Sino Biopharmaceutical (HK:1177) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sino Biopharmaceutical has received approval to submit a marketing application for its innovative drug combination, Benmelstobart Injection and Anlotinib Hydrochloride Capsules, aimed at treating the ultra-rare alveolar soft part sarcoma (ASPS). With a high tendency for metastasis and limited treatment options, this new combination therapy offers hope for improved outcomes in ASPS patients. This development marks a significant step for Sino Biopharmaceutical in expanding its portfolio of effective cancer treatments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue